This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan. The observation period will be from date of start of treatment up to a maximum of 18 months after end of treatment.
Study Type
OBSERVATIONAL
Enrollment
300
Progression-Free Survival (PFS)
Defined as the time from date of initiation of lutetium (177Lu) vipivotide tetraxetan to the date of first documented progression by investigator assessment (radiographic progression according to the most recent version of Prostate Cancer Working Group \[PCWG\] or Response Evaluation Criteria In PSMA-PET/CT \[RECIP\] 1.0, clinical progression, Prostate Specific Antigen \[PSA\] progression) or death from any cause, whichever occurs first up to 18 months post-treatment.
Time frame: up to 18 months post-treatment
Second Progression-Free Survival (PFS2)
Defined as the time from date of initiation of lutetium (177Lu) vipivotide tetraxetan to the date of first documented progression by investigator assessment (radiographic progression according to the most recent version of PCWG or RECIP 1.0, clinical progression, PSA progression) on next-line therapy or death from any cause, whichever occurs first, up to 18 months post-treatment
Time frame: up to 18 months post-treatment
Overall Survival (OS)
Defined as the time from of initiation of lutetium (177Lu) vipivotide tetraxetan until death from any cause at each cycle of lutetium (177Lu) vipivotide tetraxetan up to 18 months post-treatment
Time frame: up to 18 months post-treatment
Prostate-Specific Antigen (PSA) response rates (RR)
PSA response rates (RR): PSA30; PSA50 and PSA90 while patients are on treatment and up to a maximum of 18 months post-treatment
Time frame: up to 18 months post-treatment
Overall Response Rate (ORR)
Defined as the proportion of patients with Complete Response (CR) or Partial Response (PR) as Best Overall Response based on RECIST 1.1 or RECIP 1.0.
Time frame: up to 18 months post treatment
Novartis Pharmaceuticals
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Novartis Investigative Site
Alessandria, AL, Italy
RECRUITINGNovartis Investigative Site
Asti, AT, Italy
RECRUITINGNovartis Investigative Site
Bergamo, BG, Italy
RECRUITINGNovartis Investigative Site
Brescia, BS, Italy
RECRUITINGNovartis Investigative Site
Catania, CT, Italy
RECRUITINGNovartis Investigative Site
Meldola, FC, Italy
RECRUITINGNovartis Investigative Site
Cona, FE, Italy
RECRUITINGNovartis Investigative Site
Foggia, FG, Italy
RECRUITINGNovartis Investigative Site
Florence, FI, Italy
RECRUITINGNovartis Investigative Site
Genova, GE, Italy
RECRUITING...and 24 more locations
Duration of Response (DoR)
Defined as the onset of the first response to disease progression or death for any reason
Time frame: up to 18 months post-treatment
Proportion of patients with SSE and time to event
Proportion of patients with Symptomatic Skeletal Event (SSE ) and time to event
Time frame: up to 18 months post-treatment
Time to initiation of pain medication
Time to initiation of pain medication (if not on pain medication at baseline), assessed as time from index date (start of treatment) to date of initiation of pain medication while on treatment or at progression.
Time frame: from start of treatment to up to 18 months post-treatment
Change of pain medication
Change of pain medication (dosage or type of medication) at baseline and during treatment/follow-up.
Time frame: from baseline to up to 18 months post treatment
HRQoL - Functional Assessment of Cancer Therapy-Prostate (FACT-P)
The Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire is a relevant, worldwide tool used for providing insights into both general and prostate-specific concerns in men with prostate cancer. The FACT-P is composed of two parts, the FACT-G and the 12-item Prostate Cancer Subscale (PCS). FACT-P total score will be derived as sum of the PWB score, SWB score, EWB score FWB and PCS score and it will range from 0 to 156. Higher scores indicate better health-related quality of life.
Time frame: from cycle 1 up to 18 months post treatment
HRQoL - Brief Pain Inventory - Short Form (BPI-SF)
The Brief Pain Inventory - Short Form (BPI-SF) is a widely used tool for assessing clinical pain. The BPI allows patients to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function. Score ranges from 0 to 10. Higher score indicate worse outcomes.
Time frame: from cycle 1 up to 18 months post treatment
HRQoL - Functional Assessment of Cancer Therapy - Radionuclide Therapy (FACT-RNT)
The Functional Assessment of Cancer Therapy - Radionuclide Therapy (FACT-RNT) is used to assess health-related quality of life (HRQoL) in patients undergoing radionuclide therapy for prostate cancer, addressing general concerns and therapy-specific impacts. Score ranges from 0 to 60. The higher the score the better the quality of life.
Time frame: from cycle 1 up to 18 months post treatment
Correlation between baseline clinical and molecular characteristics and and treatment outcomes
Correlative analysis between baseline clinical and molecular characteristics (PSA, BRCA 1/2, PET PSMA quantitative analysis and Androgen Receptor \[AR\] expression) and treatment outcomes (PFS, PFS2, PSA RR, OS, ORR, DOR).
Time frame: from baseline to up to 18 months post treatment
Number of patients with hospitalized infusion of lutetium (177Lu) vipivotide tetraxetan
Number of patients with hospitalized infusion of lutetium (177Lu) vipivotide tetraxetan (type of hospitalization and length of stay ).
Time frame: 8 months (treatment duration period)
Number of patients with dosimetry performed
Number of patients with dosimetry performed before being discharged after infusion of lutetium (177Lu) vipivotide tetraxetan
Time frame: 8-9 months (treatment duration period)
Number of visits
Number of hospitalizations, emergency room visits, and hospital-based outpatient visits between Cycle 1 and the 30-day follow-up period after the last cycle, due to both adverse events (AE) (related or not to the treatment) and events not related to AE
Time frame: 9 months (from start of treatment to 30 days FUP period)
Workdays lost
Number of workdays lost due to hospitalization for infusion of lutetium (177Lu) vipivotide tetraxetan and number of workdays lost due to hospitalization due to treatment-related AE.
Time frame: 8-9 months (treatment duration period)